Unstable angina non ST elevation myocardial infarction inhibitors of RAS

Unstable angina pectoris
ICD-10	I20
ICD-9	413
DiseasesDB	8695
eMedicine	med/133
MeSH	D000787

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Smita Kohli, M.D.; Neil Gheewala, M.D. [3]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Inhibitors of Renin-Angiotensin-Aldosterone axis include:

• angiotensin converting enzyme inhibitors (ACEI) (e.g., ramipril, captopril),
• angiotensin receptor blockers, and
• aldosterone antagonists.

Mechanism of Benefit

• ACE inhibitors is amongst the class of medications which have been shown to reduce mortality in patients with MI, recent MI and left ventricular dysfunction, and high risk chronic CAD with normal left ventricular function.
• In patients who cannot tolerate ACE inhibitors, angiotensin II receptor blockers can be used.

Clinical Trial Data

HOPE trial was a landmark study in evaluating the role of ramipril(an ACE inhibitor) in a broad category of high risk patients. In this randomized, placebo controlled trial involving 9297 high risk patients, Ramipril was shown to significantly reduce the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.

ACC / AHA Guidelines (DO NOT EDIT)

“

Class I 1. An Angiotensin Converting Enzyme inhibitor (ACE) should be administered orally within the first 24 h to Unstable angina / NSTEMI patients with pulmonary congestion or LV ejection fraction (LVEF) ≤40%, in the absence of hypotension (systolic blood pressure <100 mmHg or <30 mmHg below baseline) or known contraindications to that class of medications. (Level of Evidence: A) 2. An angiotensin receptor blocker should be administered to Unstable angina / NSTEMI patients who are intolerant of ACE inhibitors and have either clinical or radiological signs of heart failure or LVEF ≤40%. (Level of Evidence: A) Class IIa 1.An ACE inhibitor administered orally within the first 24 h of Unstable angina / NSTEMI can be useful in patients without pulmonary congestion or LVEF ≤40% in the absence of hypotension (systolic blood pressure <100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to that class of medications. (Level of Evidence: B) Class III 1. An intravenous ACE inhibitor should not be given to patients within the first 24 h of Unstable angina / NSTEMI because of the increased risk of hypotension. (A possible exception may be patients with refractory hypertension.) (Level of Evidence: B)

”

Sources

• 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
• The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction